|
Gene: FSIP2 |
Gene summary for FSIP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FSIP2 | Gene ID | 401024 |
Gene name | fibrous sheath interacting protein 2 | |
Gene Alias | SPGF34 | |
Cytomap | 2q32.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q5CZC0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
401024 | FSIP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.93e-02 | 7.74e-02 | 0.0155 |
401024 | FSIP2 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.63e-05 | 5.39e-01 | -0.1088 |
401024 | FSIP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.40e-09 | 4.97e-01 | 0.0674 |
401024 | FSIP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.98e-04 | 3.12e-01 | 0.294 |
401024 | FSIP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.67e-05 | 6.67e-01 | 0.281 |
401024 | FSIP2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.76e-02 | 3.74e-01 | 0.3859 |
401024 | FSIP2 | CRC-3-11773 | Human | Colorectum | CRC | 9.36e-06 | -2.06e-01 | 0.2564 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FSIP2 | SNV | Missense_Mutation | novel | c.16165A>G | p.Ile5389Val | p.I5389V | Q5CZC0 | protein_coding | benign(0.026) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FSIP2 | SNV | Missense_Mutation | c.16412G>T | p.Arg5471Ile | p.R5471I | Q5CZC0 | protein_coding | possibly_damaging(0.516) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FSIP2 | SNV | Missense_Mutation | c.20243C>A | p.Ala6748Asp | p.A6748D | Q5CZC0 | protein_coding | possibly_damaging(0.571) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FSIP2 | SNV | Missense_Mutation | rs537076867 | c.20543N>G | p.Lys6848Arg | p.K6848R | Q5CZC0 | protein_coding | benign(0.178) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |
FSIP2 | SNV | Missense_Mutation | c.20561N>A | p.Ala6854Glu | p.A6854E | Q5CZC0 | protein_coding | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
FSIP2 | SNV | Missense_Mutation | novel | c.836N>G | p.Gln279Arg | p.Q279R | Q5CZC0 | protein_coding | possibly_damaging(0.814) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FSIP2 | SNV | Missense_Mutation | novel | c.2212N>C | p.Cys738Arg | p.C738R | Q5CZC0 | protein_coding | benign(0.069) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FSIP2 | SNV | Missense_Mutation | novel | c.14236N>A | p.Asp4746Asn | p.D4746N | Q5CZC0 | protein_coding | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FSIP2 | SNV | Missense_Mutation | rs569622525 | c.272N>A | p.Arg91Gln | p.R91Q | Q5CZC0 | protein_coding | unknown(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FSIP2 | SNV | Missense_Mutation | novel | c.3518N>A | p.Ser1173Tyr | p.S1173Y | Q5CZC0 | protein_coding | possibly_damaging(0.655) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |